pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Endocrinology & Metabolism · news · pharmadog
← back to Endocrinology & Metabolism
News · Endocrinology & Metabolism
432
stories
Sep 24, 26
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
Sep 23, 26
New approach methodologies in safety and toxicology testing: Why proving repeatability is the next hurdle for widespread adoption
fiercebiotech
Sep 23, 26
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
biospace
Sep 23, 26
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
Sep 23, 26
ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
biospace
Sep 22, 26
Viking shares surge on updated obesity drug data
biopharma dive
Sep 22, 26
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
Sep 22, 26
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
Sep 22, 26
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
Sep 22, 26
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
fiercebiotech
Sep 22, 26
Opinion: The science on relieving cancer symptoms is clear. Why isn’t insurance paying?
stat
Sep 21, 26
Novo offers low-dose CagriSema data as approval decision looms
endpoints
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 21, 26
Are healthcare systems really ready for GLP-1s?
biopharma dive
Sep 18, 26
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
Sep 18, 26
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
Sep 18, 26
Opinion: Doctors should educate patients about ‘Asian glow’ and drinking risks
stat
Sep 17, 26
Lisata deal propels Marea’s drug pipeline to Wall Street
biopharma dive
Sep 17, 26
Two more biotechs, Marea and North Immunology, do reverse mergers
endpoints
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 17, 26
Kennedy moves to revive preventive services panel with new members, after months of vacancies
stat
Sep 17, 26
Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol
fiercebiotech
Sep 17, 26
After one failed acquisition attempt, Lisata finds lifeline in Marea merger
fiercebiotech
Sep 16, 26
Novartis to pay $125M for blood-brain barrier crossing platform
biopharma dive
Sep 15, 26
STAT+: Obesity drugmakers are testing in kids as young as 6
stat
Sep 15, 26
Businesses can now apply for NIH funding
stat
Sep 15, 26
Exercise — and echocardiograms — in space protected astronauts’ hearts in study
stat
Sep 15, 26
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
Sep 14, 26
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
← prev
page 5 of 15
next →